Rockville, MD – September 24, 2018 – MockV Solutions, Inc. (MockV or the Company), a biotechnology company developing non-infectious viral clearance prediction products that address the unmet needs of process development scientists as they establish biopharmaceutical manufacturing platforms, announced today that a scientific manuscript detailing a comparative proof of concept study between Minute Virus of Mice (MVM) and its non-infectious MVM-Mock Virus Particles (MVM-MVP) and has been accepted for publication in the scientific journal Biotechnology Progress (DOI 10.1002/btpr.2694).
The study was conducted in collaboration with Texcell N.A and Asahi Kasei Bioprocess America. PlanovaTM and BioEX filters were challenged with IgG loads spiked with either MVM or MVM-MVP. Results demonstrated the ability to predict MVM flux decay and removal with the non-infectious MVM-MVP, measured via an Immuno-qPCR assay. “This data implies that MVM-MVP’s may be useful as an accurate surrogate to live MVM during nanofiltration based biopharmaceutical process development and characterization experiments”, said MockV Founder and CEO David Cetlin. “MockV’s goal is to provide these BSL-1 compatible particles as part of a commercial kit that would help scientists design robust viral clearance into their biopharmaceutical processes. This vision dovetails with ‘Quality by Design’ principles and aligns nicely with similar products on the market such as Host Cell Protein and residual Protein A Kits.”
A link to the article is provided here: https://rdcu.be/57ze
Full text of the article will be available in an upcoming print version of the journal or through contacting MockV Solutions at: firstname.lastname@example.org
About MockV Solutions Inc.
MockV Solutions, Inc. (MVS) is a biotechnology company commercializing non-infectious viral-surrogate tools to a variety of industries that currently rely on expensive and logistically challenging live virus analysis. MockV is developing a novel series of analytical assay kits which will enable biopharmaceutical process development scientists to study the efficacy of manufacturing techniques intended to remove or inactive virus, a contaminant of great concern during the manufacturing of biopharmaceuticals. These products are only approved for clinical or commercial use after their manufacturing processes demonstrate sufficient viral clearance. Currently, this is accomplished through the use of live mammalian model viruses (ex. MVM and XMuLV) in expensive and logistically challenging “spiking studies”. The lack of economical and accurate means of analyzing viral clearance during small scale process development increases the risk of failing viral clearance regulatory requirements – jeopardizing the timely approval of potentially life-altering therapies. MockV’s lead product candidate, the MVM-MVP Kit contains a non-infectious “Mock Virus Particle” (MVP) that mimics the physicochemical characteristics of live infectious MVM, as well as reagents and components to quantify MVP in solution. For further information regarding MockV Solutions, Inc., please visit the Company’s website at www.mockvsolutions.com.
About Texcell N.A.
Texcell- North America is the United States based branch of Texcell, a global contract service organization located in Frederick, MD. Texcell is committed to improving lives by supporting global therapeutic innovations. The organization provides custom cell culture, GMP cell banking, virus propagation, viral clearance, viral safety testing, toxicology, and immunology services. For more information, please visit. www.texcell.com | email@example.com